Allergy and Immunology Practices Carry a Unique Scheduling Burden
Allergy and immunology is one of the few outpatient specialties where patients must return to the office on a highly structured schedule over a period of years. Allergen immunotherapy — both subcutaneous injection (allergy shots) and sublingual tablet programs — requires a build-up phase with weekly or bi-weekly visits, followed by a maintenance phase with monthly visits for three to five years.
This creates a scheduling environment that is both high-volume and highly structured. A practice running 200 active immunotherapy patients generates 2,400 or more appointment touchpoints per year from that population alone — before counting new patient consultations, annual skin test visits, and biologic injection appointments.
The American Academy of Allergy, Asthma and Immunology estimates that immunotherapy programs are the most scheduling-intensive outpatient chronic care programs outside of dialysis — and they are managed primarily in office-based practices without the dedicated scheduling infrastructure that dialysis centers have built.
Immunotherapy Program Management: Scheduling, Adherence, and Safety
The scheduling requirements for allergen immunotherapy are non-trivial. Patients must receive injections within defined time windows based on their position in the build-up schedule. Missing an injection — or receiving one after too long an interval — may require returning to a lower dose, extending the build-up phase and the patient's overall treatment timeline.
Virtual assistants managing immunotherapy programs maintain rolling appointment calendars for each patient based on their individual build-up protocol. They send appointment reminders calibrated to the injection interval, flag patients who are overdue for their next visit, and coordinate dose-adjustment communications between the nursing staff and the scheduling queue when a patient's protocol changes.
A 2025 Journal of Allergy and Clinical Immunology survey found that practices with systematic immunotherapy recall programs maintained patient adherence rates 29% higher than practices relying on patients to self-schedule their injections.
Biologic Injection Scheduling: Mepolizumab, Dupilumab, and Omalizumab
Biologic therapies for severe asthma (mepolizumab, benralizumab), chronic urticaria (omalizumab), and atopic dermatitis/chronic rhinosinusitis (dupilumab) are increasingly administered in allergy practices as in-office injections or infusions. These medications have fixed administration intervals — every four weeks, every eight weeks — and missed doses can affect treatment efficacy.
VAs managing biologic injection programs maintain appointment calendars calibrated to each medication's dosing interval, coordinate with specialty pharmacies for medication delivery ahead of injection dates, and track authorization renewal timelines to ensure that each dose is authorized before administration. Practices running biologic programs without this systematic oversight routinely experience authorization lapses that result in missed doses and patient dissatisfaction.
Billing for Immunotherapy: SCIT and SLIT Code Complexity
Allergen immunotherapy billing involves specialized CPT codes for serum preparation, injection administration, and — for sublingual programs — antigen extract preparation. The codes differ based on whether the practice is billing for allergy testing, serum preparation, or injection administration, and payers apply different coverage rules for in-office administered doses versus patient self-administered home therapy.
VAs supporting allergy billing maintain a billing rules library for the top commercial payers and Medicare in the practice's market, verifying that each visit is coded to the correct level of the immunotherapy protocol before submission. Billing errors in immunotherapy — particularly around serum mixing codes and injection visit codes — are a common source of overpayments that trigger payer audits.
MGMA's 2025 allergy and immunology benchmarking data shows that practices with active billing oversight maintain first-pass claim acceptance rates above 93% for immunotherapy billing categories, compared to a specialty average of 86%.
Prior Authorization for Biologics: The Allergy Practice Bottleneck
Biologic therapies for asthma and atopic conditions require detailed prior authorization submissions that include pulmonary function testing results, blood eosinophil counts, documentation of previous controller therapy failure, and — for omalizumab — serum IgE testing results and weight-based dosing justification.
VAs trained in allergy-specific authorization workflows compile these documentation packages efficiently, cross-referencing the most recent lab values and physician notes to ensure each submission is complete on the first attempt. Practices that have implemented VA authorization management for their biologic programs report reducing authorization turnaround from 18 days to under 10 days.
Allergy and immunology practices evaluating virtual staffing options can review healthcare-trained VA services at Stealth Agents, which provides specialty medical practice VAs with allergy and immunotherapy workflow experience.
The Long-Term Value of Immunotherapy Program Administration
An allergy practice that retains 200 patients through a complete three-year immunotherapy program generates $1.2 million or more in cumulative revenue from that cohort, assuming average annual per-patient revenue of $2,000. Every percentage point improvement in patient adherence — driven by better scheduling management and recall — translates directly into protected revenue and better clinical outcomes for patients.
Sources
- American Academy of Allergy, Asthma and Immunology — Practice Administration and Workforce Report, 2025
- Journal of Allergy and Clinical Immunology — Immunotherapy Adherence and Scheduling Study, 2025
- Medical Group Management Association (MGMA) — Allergy and Immunology Revenue Cycle Benchmarks, 2025
- U.S. Department of Health and Human Services — HIPAA Business Associate Compliance Guidance, 2024